If you’ve spent any time reading about fasting, exercise, longevity drugs, or autophagy, you’ve bumped into two acronyms that keep showing up: mTOR and AMPK. They sound like jargon, and they kind of are, but they’re worth understanding because they’re the actual machinery underneath most of the advice. Once you see them clearly, a lot of the longevity conversation snaps into focus. You stop arguing about whether fasting “works” or whether protein is good or bad and start seeing the real question: which switch are you flipping, when, and why.

The simplest way to think about it: your cells have two big switches.

Switch 1 is mTOR. This is the grow and build switch. When mTOR is on, your cells synthesize proteins, build muscle, divide, and generally lean into anabolism. mTOR turns on when there’s plenty of food (especially amino acids), insulin is high, and growth factors are present. It’s how your body responds to abundance.

Switch 2 is AMPK. This is the conserve and clean switch. When AMPK is on, your cells stop building, start burning stored fuel, ramp up autophagy, and shift into catabolism. AMPK turns on when energy is low, when the cell senses it’s running out of ATP. It’s how your body responds to scarcity or stress.

These two switches exist in pretty much every eukaryote that’s been studied, from yeast to humans. They’re old. They evolved when food was unreliable and our cells needed a way to flip between “make hay while the sun shines” and “winter is here, conserve everything.” The problem is that most of us now live in a world where the sun is metaphorically always shining. We eat constantly, we don’t move much, and our bodies sit in chronic mTOR-on, AMPK-off mode. Whatever benefits used to come from regularly cycling between the two have largely disappeared.

A growing body of research suggests that’s a problem, and that pulling the mTOR/AMPK seesaw back toward more balance is probably one of the highest-leverage things you can do for long-term health.

Switch 1: mTOR, the build button

mTOR stands for “mechanistic target of rapamycin” (originally “mammalian target of rapamycin,” renamed when it turned out yeast had it too). It was named after rapamycin, a compound discovered in soil bacteria from Easter Island in the 1970s, which acts as its primary inhibitor. The pathway has been extensively mapped by David Sabatini’s lab and others, and it’s now understood as one of the central regulators of cell growth in all eukaryotes.

When mTOR (specifically the mTORC1 complex) is active, it does roughly the following:

• Turns on protein synthesis. Phosphorylates S6K1 and 4E-BP1, which crank up the ribosomal machinery and start translating mRNA into new proteins.
• Promotes cell growth. More mass, more division, more building.
• Suppresses autophagy. Specifically, mTOR phosphorylates ULK1 in a way that prevents autophagy from initiating. As long as mTOR is on, the cleanup crew stays home.
• Stores fat. Active mTOR signaling encourages lipogenesis.

What turns mTOR on:

• Amino acids, especially leucine. This is the strongest signal. A protein-rich meal hits mTOR hard.
• Insulin and IGF-1. Carbohydrates that spike insulin will activate mTOR through the PI3K-AKT pathway.
• Growth factors like IGF-1, EGF, and others.
• Energy abundance. When ATP is plentiful, mTOR is happy.

mTOR is not the bad guy. You need it. It’s how kids grow, how athletes recover, how injuries heal. Without working mTOR signaling, you’d never put on muscle from the gym or repair tissue after surgery. The trouble starts when mTOR is chronically on, day in and day out, with no breaks. Dysregulated mTOR signaling has been linked to cancer, type 2 diabetes, neurodegeneration, and accelerated aging.

Switch 2: AMPK, the clean-up button

AMPK stands for “AMP-activated protein kinase.” It’s the cell’s energy gauge. The way it works is elegant: AMPK monitors the ratio of AMP to ATP inside the cell. ATP is the energy currency, AMP is what’s left after ATP gets used. When energy is plentiful, ATP is high and AMP is low, so AMPK stays quiet. When energy runs low, AMP rises, and AMPK switches on. Grahame Hardie at Dundee has spent decades mapping how this works.

When AMPK is active, it does roughly the opposite of what mTOR does:

• Inhibits mTOR. Directly. AMPK phosphorylates TSC2 and Raptor, which both shut mTOR down. This is the heart of the seesaw mechanism.
• Switches on autophagy. Phosphorylates ULK1 in the opposite spot from mTOR, kicking off the cellular cleanup process.
• Burns stored fat. Activates fatty acid oxidation, the process of pulling fat out of storage and burning it for energy.
• Stops anabolism. Shuts down fatty acid synthesis, cholesterol synthesis, and protein synthesis (other than the things needed for survival).
• Boosts mitochondrial biogenesis over time, helping cells make more and better-functioning mitochondria.

What turns AMPK on:

• Low cellular energy. Fasting, especially when it’s gone on long enough to deplete glycogen.
• Exercise. Particularly intense exercise, which crashes ATP fast.
• Cold exposure. Through different upstream pathways but a similar net effect.
• Certain compounds. Metformin, berberine, and a few others that work by mildly inhibiting mitochondrial Complex I, which raises AMP and triggers AMPK.

AMPK is the body’s “we need to clean house and stretch what we have” signal. It’s the cellular version of being smart with limited resources.

The seesaw

Here’s the elegant part. mTOR and AMPK aren’t just two separate switches operating in parallel. They actively oppose each other.

When AMPK turns on, one of the first things it does is shut down mTOR. When mTOR is on, it indirectly suppresses some of AMPK’s downstream effects. They’re wired into each other in a way that ensures the cell is committed to one mode or the other at any given moment. You don’t grow and clean at the same time, just like you don’t usually run a furnace and an air conditioner at the same time.

This matters because it means almost every lifestyle intervention you can take to improve your healthspan is, mechanically, just a way of nudging this seesaw. Fasting, exercise, protein cycling, cold exposure, certain drugs: they all hit one or both of these switches.

What the seesaw looks like in mice

The clearest evidence that this whole framework actually matters for aging comes from drug experiments in mice. The most famous one: in 2009, the National Institute on Aging’s Interventions Testing Program reported that rapamycin (which directly inhibits mTOR) extends both median and maximal lifespan in mice, even when given starting late in life (600 days, the equivalent of about 60-year-old humans). The effect was 9% in males and 14% in females. A follow-up study in 2014 showed it was dose-dependent, and the effect has been replicated multiple times across labs.

Rapamycin remains the only pharmacological intervention reliably shown to extend lifespan in mammals. It works by sitting directly on mTOR and turning it off. That’s a remarkable result for an article about mechanism, because it tells you that one of these switches alone has enough leverage on aging to bend the mortality curve.

Metformin, which activates AMPK indirectly (by lowering cellular energy state via Complex I inhibition), has shown more modest and inconsistent lifespan effects in mice but is the subject of the ongoing TAME human trial precisely because of its AMPK activation and metabolic benefits.

The bigger picture: across yeast, worms, flies, and mice, reducing mTOR signaling extends lifespan. It’s one of the most robust findings in aging biology. Whether the same holds in humans is, as with autophagy, an open question. But the converging evidence is hard to ignore.

How to nudge the seesaw without drugs

The good news: the same things that trigger autophagy are, almost without exception, the things that flip these two switches in the right directions. Fasting shuts mTOR off and activates AMPK. Exercise (especially fasted, intense, and short) activates AMPK hard. Protein cycling lets mTOR rest between meals. Sleep is when the cleanup actually happens. The full breakdown of how to do this practically (the morning fasted Tabata routine, the eating window, the weekly schedule) is in the autophagy article. No reason to repeat it here. What’s worth saying in this article is that none of that advice is folk wisdom or vibes. It’s the same two switches, described from a different angle. For the bigger-picture question of how these switches fit into the Attia vs Longo vs Sinclair debate on longevity strategy, see the resilience vs slowdown piece.

The drugs

Three worth knowing about, with very different risk profiles.

Rapamycin. The cleanest mTOR inhibitor we have. Used at full immunosuppressive doses for decades in transplant patients. Increasingly used at low pulsed doses (5 to 10 mg once a week) by longevity-focused doctors and biohackers, on the theory that weekly pulsing gives you the autophagy and anti-aging effects while avoiding the chronic immunosuppression. The mechanistic argument for this dosing is what’s come to be called the “cycling hypothesis”: you want mTOR off most of the week to keep autophagy elevated, but on enough around training to allow muscle protein synthesis. In rodents, intermittent rapamycin has shown some ability to do exactly that.

The first proper human test of this idea landed in May 2026 and the results were sobering. RAPA-EX-01, led by Brad Stanfield with Matt Kaeberlein as a co-author, randomized 40 sedentary adults aged 65 to 85 to either 6 mg of weekly sirolimus or placebo. Both groups did the same home-based exercise program (chair-stands plus stationary bike) three times a week for 13 weeks. The primary endpoint was the change in 30-second chair-stand repetitions. The hope was that rapamycin would help, or at least not hurt. It didn’t help, and it looks like it modestly hurt. Both groups improved, but the rapamycin arm did about 2 fewer chair-stands by the end. The intention-to-treat analysis missed significance (p=0.089), but every secondary functional outcome (6-minute walk, grip strength, quality of life) pointed in the same direction, and the per-protocol analysis was significant (p=0.007). There were also two small safety signals: a statistically significant rise in HbA1c in the rapamycin group (HbA1c measures the percentage of your hemoglobin that’s been glycated by sugar, which reflects your average blood glucose over the previous 2 to 3 months, so a rise means glucose control is drifting in the wrong direction), and one case of pneumonia.

Peter Attia’s response to the trial is worth reading in full. His core argument: this is a small, short, narrow study on muscle adaptation, and it tells us essentially nothing about whether rapamycin slows the actual diseases that kill people (cardiovascular disease, cancer, neurodegeneration, metabolic disease). All true. But the trial does push back hard on the cleaner version of the cycling story. At minimum, weekly rapamycin in this dosing regimen seems to interfere with how older adults adapt to exercise, which is a real cost to weigh against any speculative benefit. It also reinforces a point worth sitting with: most of the “rapamycin works in humans” enthusiasm has been based on animal data and personal anecdote. When the actual RCTs start arriving, the results may be a lot messier than the discourse suggested.

One mechanistic note this trial inadvertently makes clearer: the natural cycling you get from fasted morning training followed by a protein meal is in some ways cleaner than what weekly rapamycin produces. With weekly rapamycin, you’re partially suppressing mTOR for days. With fasted training, mTOR is decisively off during the workout, then decisively on for recovery once you eat. Whether that matters in the long run is anybody’s guess, but it’s a reason not to be too discouraged by the trial if you’re getting your mTOR/AMPK cycling from lifestyle rather than drugs.

Metformin. A diabetes drug for 60+ years. Activates AMPK indirectly via mild Complex I inhibition. Cheap, well-tolerated, prescribed to millions. Whether it extends life in non-diabetics is the question the TAME trial is trying to answer. There’s some evidence it blunts the muscle-building response to exercise, which is a real consideration if you’re training.

Berberine. A plant alkaloid from goldenseal and other sources. Activates AMPK through the same Complex I mechanism as metformin, less potently. Available as a supplement. Not a drug, not regulated, and not as well-studied, but the mechanism is real. Some longevity people use it as a metformin substitute when they can’t get a prescription. Caveat-heavy; do your own research.

GLP-1 agonists (Ozempic, Mounjaro) are worth mentioning even though they hit different pathways primarily. Their dramatic effects on weight and metabolic health probably reroute the mTOR/AMPK balance indirectly through reduced food intake and improved insulin sensitivity, but the primary mechanism is elsewhere.

What doesn’t really matter

A few things that get marketed as mTOR or AMPK levers without much support:

• Most “longevity supplements” don’t move either pathway in any meaningful, dose-confirmed way in humans.
• Specific “AMPK-activating” foods marketed online are mostly weak signal at best. Berberine is the strongest of the supplement-grade options, and even that’s modest.
• “Anti-mTOR diets” are a marketing layer on top of “lower-protein diets” or “intermittent fasting.” Just call it what it is.

Putting it together

A practical view: your goal isn’t to permanently turn off mTOR or permanently leave AMPK on. Both extremes are bad. Permanent mTOR-off means you’d lose muscle, slow healing, and weaken your immune system. Permanent AMPK-on isn’t really possible in the long run anyway.

The goal is to cycle between them with some intention. Most modern adults get plenty of mTOR time and almost no AMPK time. A reasonable rebalancing looks like:

• Eat in a 10-hour window most days. Tighter sometimes.
• Train hard several times a week, ideally fasted some of those times.
• Get most of your protein in two or three solid meals rather than constant grazing.
• Sleep 7 to 9 hours.
• Try a 24-hour fast every few weeks if you can tolerate it. This pushes the seesaw harder than time-restricted eating alone.
• Consider drugs only with medical input. Rapamycin and metformin are not casual supplements.

That’s it. That’s the whole longevity playbook compressed into mechanism. Most of the advice you read elsewhere is just a different surface description of these same two switches.

A word of caution

Both pathways are extraordinarily complex and this article simplified them aggressively. mTORC1 and mTORC2 do different things. AMPK has dozens of downstream targets. The interplay involves TSC1/TSC2, Rheb, Raptor, Rictor, LKB1, and a dozen other proteins worth knowing about if you want to go deeper. The two-switches frame is a useful first approximation, not the whole story.

Also: if you have any medical conditions, are pregnant, are training competitively, or are on medications, get professional input before making big changes. Particularly with rapamycin and metformin, the difference between “potentially useful longevity intervention” and “actively harmful” can be subtle and personal.

The rest of it (eat with intention, fast sometimes, train hard, sleep well) is the same advice your cells have been quietly giving you all along.

---

References

1. Saxton, R.A., Sabatini, D.M. (2017). mTOR Signaling in Growth, Metabolism, and Disease. Cell, 168(6), 960–976. https://www.sciencedirect.com/science/article/pii/S0092867417301824
2. Liu, G.Y., Sabatini, D.M. (2020). mTOR at the nexus of nutrition, growth, ageing and disease. Nature Reviews Molecular Cell Biology, 21, 183–203. https://www.nature.com/articles/s41580-019-0199-y
3. Hardie, D.G., Ross, F.A., Hawley, S.A. (2012). AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nature Reviews Molecular Cell Biology, 13, 251–262. https://www.nature.com/articles/nrm3311
4. Hardie, D.G. (2014). AMP-activated protein kinase: a key regulator of energy balance with many roles in human disease. Journal of Internal Medicine. https://onlinelibrary.wiley.com/doi/full/10.1111/joim.12268
5. Garcia, D., Shaw, R.J. (2017). AMPK: Mechanisms of Cellular Energy Sensing and Restoration of Metabolic Balance. Molecular Cell. https://pmc.ncbi.nlm.nih.gov/articles/PMC5553560/
6. Harrison, D.E., Strong, R., Sharp, Z.D., et al. (2009). Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature, 460, 392–395. https://www.nature.com/articles/nature08221
7. Miller, R.A., Harrison, D.E., Astle, C.M., et al. (2014). Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032600/
8. Strong, R., Miller, R.A., Astle, C.M., et al. (2020). Rapamycin-mediated mouse lifespan extension: Late-life dosage regimes with sex-specific effects. Aging Cell. https://onlinelibrary.wiley.com/doi/full/10.1111/acel.13269
9. Foretz, M., Guigas, B., Bertrand, L., Pollak, M., Viollet, B. (2014). Metformin: from mechanisms of action to therapies. Cell Metabolism.
10. Stanfield, B., Leroux, B., Kaeberlein, M., Jones, J., Lucas, R. (2026). Exercise and weekly sirolimus (rapamycin) in older adults: RAPA-EX-01 randomised, double-blind, placebo-controlled trial. Journal of Cachexia, Sarcopenia and Muscle, 17(2), e70274. https://onlinelibrary.wiley.com/doi/10.1002/jcsm.70274
11. Attia, P., Yeater, T., Rae, M. (May 2, 2026). Disappointing results from the first rapamycin-plus-exercise trial. https://peterattiamd.com/rapamycin-plus-exercise-trial/
12. Moel, M., Harinath, G., Lee, V., et al. (2025). Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12074816/